{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:11:38Z","timestamp":1760919098846,"version":"build-2065373602"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jceh.2014.06.008","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T09:17:33Z","timestamp":1403774253000},"page":"241-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Designing Immune Therapy for Chronic Hepatitis B"],"prefix":"10.1016","volume":"4","author":[{"given":"Sheikh Mohammad","family":"Fazle Akbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamun","family":"Al-Mahtab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2014.06.008_bib1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1478-3231.2012.02805.x","article-title":"Natural history of chronic hepatitis B: what exactly has REVEAL revealed?","volume":"32","author":"Iloeje","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2014.06.008_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-0030-1267537","article-title":"Management of chronic hepatitis B; status and challenges beyond treatment guidelines","volume":"30","author":"Wiegand","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jceh.2014.06.008_bib4","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1517\/14656566.2011.590474","article-title":"Recent advances in the treatment of chronic hepatitis B","volume":"12","author":"Lin","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jceh.2014.06.008_bib5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(01)00005-8","article-title":"Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach","volume":"34","author":"Camma","year":"2001","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2014.06.008_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1478-3231.2010.02406.x","article-title":"Milestones and perspectives in viral hepatitis B","volume":"31","author":"Hadziyannis","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2014.06.008_bib8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.510290312","article-title":"Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection","volume":"29","author":"Lin","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2014.06.008_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2014.06.008_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1478-3231.2008.01941.x","article-title":"Natural history of chronic hepatitis B virus infection and long-term outcome under treatment","volume":"29","author":"Liaw","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2014.06.008_bib11","first-page":"1","article-title":"Management of chronic hepatitis B","volume":"174","author":"Wilt","year":"2008","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"10.1016\/j.jceh.2014.06.008_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-150-2-200901200-00101","article-title":"Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference","volume":"150","author":"Shamliyan","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2014.06.008_bib13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00535-011-0401-2","article-title":"Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration","volume":"46","author":"Akbar","year":"2011","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jceh.2014.06.008_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.patbio.2009.11.001","article-title":"Pathogenesis of hepatitis B virus infection","volume":"58","author":"Chisari","year":"2010","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.jceh.2014.06.008_bib15","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2014.06.008_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jceh.2014.06.008_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cld.2007.08.001","article-title":"The immunology of hepatitis B","volume":"11","author":"Vierling","year":"2007","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2014.06.008_bib18","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2014.06.008_bib19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/hep.510290452","article-title":"What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B","volume":"29","author":"Koziel","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2014.06.008_bib20","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","article-title":"The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection","volume":"191","author":"Maini","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jceh.2014.06.008_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0168-8278(05)80580-X","article-title":"Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects","volume":"19","author":"Tilg","year":"1993","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/(SICI)1096-9071(199803)54:3<167::AID-JMV4>3.0.CO;2-3","article-title":"Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B","volume":"54","author":"Artillo","year":"1998","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jceh.2014.06.008_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0168-8278(00)80078-1","article-title":"A\u00a0phase I\/II study of recombinant human interleukin-12 in patients with chronic hepatitis B","volume":"32","author":"Carre\u00f1o","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib24","first-page":"1156","article-title":"Changes in cytokine production during therapy with granulocyte-macrophage colony-stimulating factor in patients with chronic hepatitis B","volume":"20","author":"Mart\u00edn","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2014.06.008_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.1840180207","article-title":"Levamisole and interferon in children with chronic hepatitis B","volume":"18","author":"Ruiz-Moreno","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2014.06.008_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0168-8278(95)80306-8","article-title":"Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B","volume":"23","author":"Farhat","year":"1995","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3851\/IMP1295","article-title":"Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I\/II trial","volume":"14","author":"Woltman","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jceh.2014.06.008_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00535-003-1098-7","article-title":"Propagermanium: a nonspecific immune modulator for chronic hepatitis B","volume":"38","author":"Hirayama","year":"2003","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jceh.2014.06.008_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1478-3231.2004.0935.x","article-title":"Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial","volume":"24","author":"Israeli","year":"2004","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2014.06.008_bib30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2893.2005.00633.x","article-title":"The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial","volume":"12","author":"Iino","year":"2005","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2014.06.008_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.antiviral.2007.10.014","article-title":"Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis","volume":"77","author":"Yang","year":"2008","journal-title":"Antiviral Res"},{"issue":"8918","key":"10.1016\/j.jceh.2014.06.008_bib32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(94)91384-6","article-title":"Specific vaccine therapy in chronic hepatitis B infection","volume":"344","author":"Pol","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2014.06.008_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1440-1746.2002.02652.x","article-title":"Therapeutic vaccination in chronic hepatitis B","volume":"17","author":"Senturk","year":"2002","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib34","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1016\/j.vaccine.2010.09.093","article-title":"Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine","volume":"28","author":"Wang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jceh.2014.06.008_bib35","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91126-X","article-title":"Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy","volume":"345","author":"Wen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2014.06.008_bib36","doi-asserted-by":"crossref","first-page":"e2565","DOI":"10.1371\/journal.pone.0002565","article-title":"A\u00a0randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients","volume":"3","author":"Xu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2014.06.008_bib37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/jmv.2165","article-title":"Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B","volume":"66","author":"Dahmen","year":"2002","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jceh.2014.06.008_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2004.07.004","article-title":"In\u00a0vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B","volume":"32","author":"Horiike","year":"2005","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jceh.2014.06.008_bib39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1440-1746.2004.03358.x","article-title":"Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B","volume":"19","author":"Helvaci","year":"2004","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib40","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1128\/AAC.00276-09","article-title":"Randomized controlled study investigating viral suppression and serological response following pre-S1\/pre-S2\/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B","volume":"53","author":"Hoa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jceh.2014.06.008_bib41","first-page":"421A","article-title":"Phase 1 study of a potent adjuvanted hepatitis B vaccine (HBV\/MF59) for therapy of chronic hepatitis","volume":"30","author":"Wright","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2014.06.008_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2893.2012.01589.x","article-title":"A\u00a0pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in\u00a0vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy","volume":"19","author":"Yang","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2014.06.008_bib43","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3748\/wjg.v11.i12.1806","article-title":"Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study","volume":"11","author":"Chen","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2014.06.008_bib44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2893.2010.01320.x","article-title":"Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B","volume":"18","author":"Akbar","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2014.06.008_bib45","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.vaccine.2010.01.038","article-title":"Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers","volume":"28","author":"Luo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jceh.2014.06.008_bib46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1440-1746.2003.02950.x","article-title":"Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection","volume":"18","author":"Dikici","year":"2003","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib47","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0168-8278(01)00028-9","article-title":"Efficacy and limitations of a specific immunotherapy in chronic hepatitis B","volume":"34","author":"Pol","year":"2001","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2014.06.008_bib48","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","article-title":"Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine","volume":"25","author":"Vandepapeli\u00e8re","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jceh.2014.06.008_bib49","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0016-5085(99)70289-1","article-title":"Direct ex\u00a0vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection","volume":"117","author":"Maini","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2014.06.008_bib50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3851\/IMP1637","article-title":"Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection","volume":"15","author":"Akbar","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jceh.2014.06.008_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2012.07.011","article-title":"Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus","volume":"96","author":"Akbar","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jceh.2014.06.008_bib52","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s12072-013-9486-4","article-title":"Therapeutic potential of a combined hepatitis B surface antigen and core antigen vaccine in patients with chronic hepatitis B","volume":"784","author":"Al-Mahtab","year":"2013","journal-title":"Hepatol Int"},{"year":"2013","series-title":"A\u00a0Phase III Clinical Trial with a Therapeutic Vaccine Containing Both HBsAg and HBcAg Administered via Both Mucosal and Parenteral Routes in Patients with Chronic Hepatitis B","author":"Akbar","key":"10.1016\/j.jceh.2014.06.008_bib53"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688314003181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688314003181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:01:57Z","timestamp":1760853717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688314003181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0973688314003181"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2014.06.008","relation":{},"ISSN":["0973-6883"],"issn-type":[{"type":"print","value":"0973-6883"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designing Immune Therapy for Chronic Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2014.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 INASL. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}